The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | Novel therapeutic regimens being explored in PTCL
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, highlights the importance of exploring novel therapeutic combinations in peripheral T-cell lymphoma (PTCL), and shares some insights into the Alliance A059102 study (NCT04803201), which is evaluating the efficacy of azacitidine or duvelisib in combination with CHOP/CHO(E)P chemotherapy in patients with PTCL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
